Pulse Biosciences, Inc (NASDAQ:PLSE) Receives Average Rating of “Moderate Buy” from Analysts

Pulse Biosciences, Inc (NASDAQ:PLSE) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $45.25.

PLSE has been the topic of several research reports. Mizuho set a $45.00 target price on Pulse Biosciences in a research report on Monday, August 10th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th.

Insiders Place Their Bets

In related news, COO Liane Teplitsky acquired 1,001 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was purchased at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the completion of the purchase, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at $204,545.25. The trade was a 32.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 4,095 shares of company stock valued at $199,931 in the last quarter. Corporate insiders own 74.00% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter valued at about $28,000. Tower Research Capital LLC TRC lifted its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in Pulse Biosciences during the second quarter worth about $158,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Trading Up 2.8%

Shares of PLSE stock opened at $54.43 on Friday. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $58.90. The stock’s fifty day simple moving average is $39.87 and its 200-day simple moving average is $28.84. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -46.13 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, sell-side analysts predict that Pulse Biosciences will post -1.29 EPS for the current year.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.